Weed company Curaleaf Holdings Inc. got a warning from the FDA for claiming CBD products can treat diseases.
On July 23, 2019, the Food and Drug Administration (FDA) sent a letter to the company against making “unsubstantiated claims” about CBD. The administration reviewed Curaleaf’s website and social accounts and flagged products like CBD lotion, patches, tinctures, and vapes.
“…[the] products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.”
The FDA letter cited Curaleaf’s claims that CBD can treat conditions like chronic pain, Parkinson’s and Alzheimer’s disease, depression, and anxiety. A Curaleaf spokesperson told MarketWatch that the company is reviewing the FDA’s letter and intends to remain compliant and cooperative.
CVS has said it will pull Curaleaf products flagged by the FDA. The administration has asked Curaleaf to respond with plans to address the violations within 15 days.
“Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction,” the letter stated.